Denali Therapeutics (DNLI) Profit After Tax: 2017-2024
Historic Profit After Tax for Denali Therapeutics (DNLI) over the last 8 years, with Dec 2024 value amounting to -$114.8 million.
- Denali Therapeutics' Profit After Tax rose 3.95% to -$114.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$422.8 million, marking a year-over-year decrease of 191.12%. This contributed to the annual value of -$422.8 million for FY2024, which is 191.12% down from last year.
- As of Q4 2024, Denali Therapeutics' Profit After Tax stood at -$114.8 million, which was down 7.05% from -$107.2 million recorded in Q3 2024.
- In the past 5 years, Denali Therapeutics' Profit After Tax ranged from a high of $244.9 million in Q4 2020 and a low of -$119.5 million during Q4 2023.
- For the 3-year period, Denali Therapeutics' Profit After Tax averaged around -$74.5 million, with its median value being -$100.6 million (2023).
- Per our database at Business Quant, Denali Therapeutics' Profit After Tax soared by 553.28% in 2020 and then slumped by 154.00% in 2024.
- Over the past 5 years, Denali Therapeutics' Profit After Tax (Quarterly) stood at $244.9 million in 2020, then crashed by 130.73% to -$75.3 million in 2021, then crashed by 31.11% to -$98.7 million in 2022, then fell by 21.07% to -$119.5 million in 2023, then increased by 3.95% to -$114.8 million in 2024.
- Its Profit After Tax was -$114.8 million in Q4 2024, compared to -$107.2 million in Q3 2024 and -$99.0 million in Q2 2024.